| A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) |
Ongoing |
Adagrasib(BMS-986503/KRAZATI®) |
3 |
CA2390004 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Ongoing |
Lasertinib |
2 |
61186372NSC2012 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients with ULcerative Colitis and Crohn’s DiseasE in Real-World Practice in Saudi Arabia (EAGLE) |
Ongoing |
Guselkumab( Tremfya) |
4 |
CNTO1959IB |
Al Salama Hospital (Jeddah) |
| A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants with Classic Congenital Adrenal Hyperplasia |
Ongoing |
Atumelnant |
3 |
CRN04894-12 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype |
Ongoing |
Lunsekimig |
2 |
EFC18243 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh) |
| A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 |
Ongoing |
MRNA 3705 |
2 |
mRNA-3705-P101-EXT |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6). |
Ongoing |
KYV101 |
2 |
KYV101-006 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High (≥50% Of Tumor Cel Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer. |
Ongoing |
Sigvotatug Vedotin and Pembrolizuma |
3 |
C5751003 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (YOSEMITE) |
Ongoing |
Zodasiran |
3 |
AROANG3-3001 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer. |
Ongoing |
Sacituzumab and Pembrolizumab |
3 |
MK-6482-033-01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
